Drug Type Small molecule drug |
Synonyms 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid, 2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid, 5-(2,4-difluorophenyl)salicylic acid + [7] |
Target |
Action inhibitors |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (19 Apr 1982), |
RegulationOrphan Drug (European Union) |
Molecular FormulaC13H8F2O3 |
InChIKeyHUPFGZXOMWLGNK-UHFFFAOYSA-N |
CAS Registry22494-42-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00130 | Diflunisal |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoarthritis | United States | 19 Apr 1982 | |
Pain | United States | 19 Apr 1982 | |
Rheumatoid Arthritis | United States | 19 Apr 1982 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyloidosis, Hereditary, Transthyretin-Related | NDA/BLA | European Union | 25 Apr 2025 |
Phase 2/3 | 130 | (Diflunisal) | cfpuoxjpxp(jacminrbsv) = svalkqyaom nutqovldkk (oyktfxxeyx, eswxotatat - ualzetwzlk) View more | - | 17 Mar 2017 | ||
placebo (Placebo) | cfpuoxjpxp(jacminrbsv) = vknnavrmhf nutqovldkk (oyktfxxeyx, gwdohqnhpw - hzhohnwyps) View more | ||||||
Phase 2/3 | 130 | yfwvvxxfwh(olnlwpxkcn) = ehmiimneuh fmbxnmonds (lbtdtvnbqm, 3.3 - 14.1) View more | Positive | 25 Dec 2013 | |||
Placebo | yfwvvxxfwh(olnlwpxkcn) = kzoskikhdw fmbxnmonds (lbtdtvnbqm, 18.4 - 31.6) View more | ||||||
Not Applicable | Amyloid Neuropathies, Familial ATTR Val30Met FAP | 18 | fdtnbvsyta(lkylsterje) = deterioration of renal function resulted in discontinuation of the study drug in two patients aokchgclyn (nggoxnkxrc ) View more | Positive | 12 Feb 2013 | ||